The Prevalence and Clinical Characteristics of Children With Local Allergic Rhinitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* To determine prevalence of local allergic rhinitis (LAR)
* To evaluate clinical characteristic and severity of local allergic rhinitis
* To measure changing of tryptase and Specific IgE for Dermatophagoides pteronyssinus (Dp) after nasal allergen provocation test (NAPT)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Development of Allergic Rhinitis in Children Previously Diagnosed as Nonallergic Rhinitis

NCT01068808

Allergic Rhinitis (Disorder)

COMPLETED

Quality of Life of Patients With a History of Drug Allergy in Thailand

NCT01666470

Quality of Life

COMPLETED

Optimal Concentration of Dermatophagoides Pteronyssinus (Dp) Allergen Extract for Skin Prick Test (SPT) of Thai Population

NCT01172613

Rhinitis, Allergic, Perennial Rhinitis, Allergic, Seasonal Skin Prick Test

UNKNOWN

Comparison Between Local and Imported Skin Prick Testing Result of Rat and Mouse Allergen Extracts

NCT03645161

Allergic Rhinitis Due to Animal Hair and Dander

COMPLETED NA

Real-life Management and Therapeutic Outcome of Patients With Chronic Rhinitis and Chronic Urticaria in Thailand

NCT02000648

Allergic Rhinitis Non-allergic Rhinitis Chronic Urticaria

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Children 8-18 years with NAR were recruited. A NAPT with Der p 1 solutions (NAPT-DP) at 200 AU/mL, 600 AU/mL and 2000 AU/mL at 15-minute interval was performed, respectively. The immediate responses to NAPT-DP were assessed using symptoms score, peak nasal inspiratory flow (PNIF) and acoustic rhinometry (ARM). The nasal tryptase and sIgE-DP were measured at baseline, 15 min and 1 h after positive NAPT-DP. Allergic rhinitis (AR) patients were used as positive control.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Other Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

nonallergic rhinitis

nonallergic rhinitis nasal allergen provocation test

Group Type OTHER

nasal allergen provocation test

Intervention Type PROCEDURE

nasal allergen provocation test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nasal allergen provocation test

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children 8-15 years who were diagnosed with nonallergic rhinitis (NAR) at least 1 year
* No respiratory infections in the previous 4 weeks
* No following treatment of
* systemic corticosteroid 4 weeks
* intranasal corticosteroid 2 weeks
* oral antihistamine 1 week
* leukotriene antagonist 1 week

Exclusion Criteria

* Patients with underlying disease:
* chronic rhinosinusitis and nasal polyp
* immunological disease
* chronic renal disease
* hepatobiliary disease
* cardiovascular disease
* cancer
* Parental withdraw consent
* Patient with uncontrolled asthma, peak expiratory flow rate (PEFR) \< 80% of predicted

Minimum Eligible Age

8 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No